AstraZeneca (NYSE:AZN) presented Phase III data for tozorakimab, an investigational anti-IL-33 monoclonal antibody, at the 2026 European Respiratory Society Congress in Barcelona. The trials demonstrated statistically significant reductions in moderate-to-severe exacerbations among patients with chronic obstructive pulmonary disease (COPD). Specifically, the OBERON trial showed a 29% reduction, while the TITANIA trial reported a 34% reduction in exacerbations for former smokers. The FDA has granted priority review for tozorakimab, with a decision expected in the first quarter of 2027.
The trials enrolled patients with varying eosinophil levels, reporting a 30% reduction in exacerbation rates in current and former smokers overall. Additionally, reductions in severe exacerbations requiring emergency care or hospitalization were noted at 36% and 33% in the respective trials. While the St. George’s Respiratory Questionnaire did not achieve statistical significance, the Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms score indicated symptom improvements.
AstraZeneca estimates that by 2030, around 6 million COPD patients could be eligible for a biologic, positioning tozorakimab as a potential first-line treatment option. The company projects that tozorakimab could generate peak sales exceeding $5 billion across multiple indications, contributing to its broader pipeline that includes various respiratory and inflammatory conditions.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
